Join our newsletter
Get updated info, tips and news about breastfeeding, e-lactancia project and other initiatives from APILAM
Legitimation: Consent of the interested party
As a user and interested I inform you that the data you provide will be located on the servers of MailChimp (email marketing provider of APILAM) outside the EU in the USA. MailChimp is covered by the EU-US Privacy Shield agreement, whose information is available here, approved by the European Committee for Data Protection. See Mailchimp's privacy policy. (https://mailchimp.com/legal/privacy/).
The fact that you do not enter the personal data that appear on the form as mandatory may have the consequence that we can not meet your request.
You can exercise your rights of access, rectification, limitation and delete the data in apilam.es@gmail.com as well as the right to file a claim with a control authority.
You can consult the additional and detailed information on Data Protection on this website: http://e-lactancia.org, as well as consult our own privacy policy.
At latest update no published data on excretion into breast milk were found.
The small dose and low plasma absorption of most topical ophthalmic preparations make it unlikely the passage of significant amount of such a product to breast milk, so the use as ophthalmic eye drops poses a very low risk while breastfeeding.
In addition, its short half-life and high plasma protein binding capacity make it even more unlikely any passage to the breast milk.
After application, press onto the tear sac or close the eyelids tightly for a couple of minutes (nasolacrimal occlusion) to minimize systemic absorption.